Key market opportunities for mesenchymal stem cells include advancements in regenerative medicine, growing investments in R&D ...
FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company ...
Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); ...
Living tissues do not change through biology alone. They are shaped by a constant dialogue among forces, chemicals, and ...
Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST)- Pivotal data from Phase 3 PEAK ...
Colon cancer symptoms in women are similar to those in men, but they can be confused with gynecological issues, like cramping ...
MSC programs often fail at scale due to early design choices. Dr. John Shyu explains how culture systems, media, and process ...
R3 Stem Cell's trademark for "Regenerative Trifecta" formalizes the brand identity of a clinical protocol used across ...
According to the statistical yearbook “Malignant Neoplasms,” Armenia recorded 218 newly diagnosed ovarian cancer cases in ...
Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation ...
Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results